---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035503"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-07-30T21:29:16+00:00"
generated_at: "2026-07-30T21:30:03.997678+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting

## Summary
- Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.
- Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.
- Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.
- Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027.

## SEC filing metadata
- accession: 0001493152-26-035503
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-07-30T21:29:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/0001493152-26-035503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035503
- JSON: https://secwatch.observer/filing/0001493152-26-035503.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.